Eight blockbuster drugs are expected to generate over $3bn in peak sales each according to Novartis CEO Vas Narasimhan.

Additionally, Daiichi Sankyo has partnered with MSD in a $22bn deal to advance ADCs targeting HER3, B7-H3, and CDH6. Each therapy in this pipeline utilises Daiichi Sankyo’s DXd technology. Enhertu and ...

Intra-Cellular’s clinical-stage pipeline is promising, with pipeline agents under development for a wide range of neurological indications.

This month, pharma companies have announced plans to increase the prices of more than 250 branded drugs in the US.

Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment Leqembi (lecanemab-irmb) after the US Food and Drug Administration (FDA) ...

US-based Normunity has raised $75m in a Series B funding round to support the clinical development of its lead programme, NRM-823, a potential first-in-class T-cell engager (TCE) targeting solid ...

Amgen presented data about its obesity drug at JP Morgan 2025, stating it hopes the once-monthly dosing will make it an attractive therapy.

In a new webinar, industry experts explore how innovative technology and direct patient communication are transforming medication adherence in the UK.

IFF Pharma Solutions is a winner in the Marketing category in the 2024 Pharmaceutical Technology Excellence Awards.

Leading CRDMO Syngene is a Triple Category Award winner in the 2024 Pharmaceutical Technology Excellence Awards.